23andMe sold out and sold your genetic info, no consent necessary 

Regeneron’s $256 million acquisition of 23andMe, announced last month, isn’t just a salvage deal — it’s a genomic land grab.

A pharmaceutical titan now owns the intimate biological blueprints of 15 million people. There were no new terms and there was no consent. Just signatures, court approval and silence. 

23andMe didn’t sell a product. It sold trust. It marketed curiosity, promised empowerment, and built a goldmine from spit tubes and ancestry pie charts. But trust isn’t an asset you can auction off.